Description of Company and Basis of Presentation (Details) $ / shares in Units, $ in Millions		6 Months Ended
	Jul. 27, 2017 USD ($) $ / shares	Jun. 30, 2017 USD ($) Patient Class
Description of Company and Basis of Presentation [Abstract]
Number of patients tested for various types of cancer | Patient		600
Number of years Orphan Drug Designation provides several benefits of market exclusivity after approval		7 years
Number of years soft tissue sarcomas confers market among other benefits		10 years
Subsequent Event [Line Items]
Number of classes of ultra-high potency drug conjugates | Class		2
NantCell, Inc [Member]
Subsequent Event [Line Items]
Net proceeds received from the sale of common stock		$ 13.0
Subsequent Event [Member] | NantCell, Inc [Member]
Subsequent Event [Line Items]
Net proceeds received from the sale of common stock	$ 13.0
Common stock, share price (in dollars per share) | $ / shares	$ 1.10
Percentage of common stock premium at market price	92.00%
Subsequent Event [Member] | NantCell, Inc [Member] | Maximum [Member]
Subsequent Event [Line Items]
Milestone payments entitled to receive under license agreement	$ 343.0